Fundraising FoxLakewood-Amedex
Sarasota, US · Delaware corporation
Find your way into Lakewood-Amedex
Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
Founders & leadership
PA
Paul Anthony DiTullioExecutive
RF
Richard Ford HammExecutive
SP
Steve ParkinsonExecutive
Board
GE
Geoffrey E CoxBoard director
SM
Stephen M MileyBoard director
TW
Teddy Wallace BrownBoard director
Funding
SEC filings, press & company announcements$31.1M disclosed across 3 of 5 rounds · 2014–2026
- Undisclosed amountSeries CMay 2026Source ↗
▶$24.1MraisedJan 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$24.1MraisedJan 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Geoffrey CoxDirector
- Charles WrightDirector
- Leonard DeRomaDirector
- Peter CorrDirector
- Offering amount
- $40M
- Amount sold
- $24.1M
- Minimum investment
- $250K
- Proceeds to insiders
- $850K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$456KraisedDec 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$456KraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven ParkinsonExecutive Officer, Director
- Patrick Coleman O'ConnorExecutive Officer
- Peter CeccacciExecutive Officer
- Geoffrey Frank CoxDirector
- Leonard James DeRomaDirector
- Charles Frederick WrightDirector
- Offering amount
- $15M
- Amount sold
- $456K
- Minimum investment
- $100K
- Sales commissions
- $12K
- Placement agents
- Sargasso Consulting LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedSep 2015 · 75 investors · BiotechnologyRule 506(b)
▶$6.6MraisedSep 2015 · 75 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul Anthony DiTullioExecutive Officer, Director
- Geoffrey E CoxDirector
- Richard Ford HammExecutive Officer
- Steve ParkinsonExecutive Officer, Director
- Stephen M MileyDirector
- Teddy Wallace BrownDirector
- Offering amount
- $10M
- Amount sold
- $6.6M
- Minimum investment
- $26K
- Sales commissions
- $292.6K
- Proceeds to insiders
- $960K
- Placement agents
- Scarsdale Equities LLC, Capital Guardian, LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapIronwood Pharmaceuticals6 shared keywordsIronwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases. It concentrates on GI drug discovery and care for patients suffering from digestive diseases.
IQVIA6 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Eli Lilly5 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies competing with Lakewood-Amedex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Lakewood-Amedex (LABT) raises $7.5M in 12% preferredstocktitan.net · Aug 2026Frequently asked questions
- What does Lakewood-Amedex do?
- Lakewood Amedex develops antimicrobial compounds, specifically Bisphosphocin® formulations, designed as locally delivered bactericides and fungicides with potential medical applications. The company focuses on advancing antimicrobial technology to address infection treatment needs.
- How much funding has Lakewood-Amedex raised?
- Lakewood-Amedex has disclosed $31.1M raised across 3 of its 5 known rounds.
- Where is Lakewood-Amedex headquartered?
- Lakewood-Amedex is headquartered in Sarasota, US.